Skip to main content
Premium Trial:

Request an Annual Quote

Jim Richey, Charles Campbell, Pieter Muntendam, Daniel Von Hoff, Raymond Woosley

Premium

Jim Richey has become a senior advisor of business development, and Charles Campbell a member of the scientific advisory board of Lumera, the Bothell, Wash.-based company said last month.

Richey has held senior executive positions at LJL BioSystems, PerSeptive BioSystems, Pharmacia Biosensor, and Pharmacia Biotech.

Campbell is a professor of chemistry at the University of Washington and a co-director of the University of Washington/PNNL Joint Institute for Nanotechnology.


Pieter Muntendam has become the new president of BG Medicine, formerly Beyond Genomics, the systems biology firm announced last week.

Muntendam has previously held senior executive positions at Glaxo Wellcome (now GlaxoSmithKline), Johnson & Johnson, NetNumina, Organon International and others.

He received his MD from Leiden University in The Netherlands.


Daniel Von Hoff and Raymond Woosley have joined the scientific advisory board of HTG the gene expression assay-technology and services company said this week.

Von Hoff was named to the National Cancer Advisory Board in 2004 and has held positions at the American Association for Cancer Research, the American College of Physicians, and the American Society of Clinical Oncology. He is a founder of ILEX Oncology, which was recently acquired by Genzyme.

Woosley recently became president of the Critical Path Institute and has held administrative positions at the University of Arizona and Georgetown University.

 

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.